Northern Mariana Islands

Reimbursed Care Access

The Commonwealth of the Northern Mariana Islands (CNMI) is a United States territory and is subject to U.S. federal drug scheduling and FDA regulatory regimes; as a result, most classical psychedelics remain federally scheduled with no general medical/reimbursement pathway outside of approved drugs or regulated clinical research. Esketamine (Spravato) — an FDA‑approved, REMS‑restricted nasal spray — is available under the same REMS restrictions that apply across U.S. jurisdictions, though local availability and payer coverage in CNMI depend on local providers, private insurers, and territorial Medicaid/benefit arrangements. Off‑label ketamine infusion treatments are provided in private clinics in U.S. jurisdictions but are generally not reimbursed by Medicare/Medicaid or most commercial insurers; other listed compounds are federally Schedule I with access only via approved clinical trials or narrowly defined religious exemptions. [https://www.spravatorems.com/|SPRAVATO REMS] [https://portal.ct.gov/dcp/drug-control-division/drug-control/tryptamines|DEA/CFR summary and tryptamines overview].